Table 1 Roles and mechanisms of FAO in chemotherapy resistance.
From: The role and mechanism of fatty acid oxidation in cancer drug resistance
Cancer | Drug | Mechanism | Role | Ref |
|---|---|---|---|---|
OC | Cisplatin | – | PR | [50] |
GC | Cisplatin | The up-regulates of the NPRA strengthened the FAO | PR | [57] |
GC/CRC | Oxaliplatin | NFATc3 enhances FAO by up-regulating CPT2 | PR | [58] |
CRC | Oxaliplatin | – | PR | [59] |
GC | 5-FU/Oxaliplatin | LncRNA HCP5 induces the expression of PGC1α through miR-3619-5p, promotes the activation of CPT1 by PGC1α/CEBPB complex, and enhances FAO | PR | [60] |
GC | FU/Oxaliplatin | TGF-β1 increased the expression of lncRNA MACC1-AS1 by activating SMAD2/3, and lncRNA MACC1-AS1 targeted miR-145-5p to up-regulate FAO | PR | [61] |
OC | Cisplatin | COL11A1 binds to DDR2 to activate the Src/Akt/AMPK pathway and enhance FAO | PR | [64] |
OC | Cisplatin | COL11A1 enhances FAO by up-regulating HSP27 | PR | |
OC | Cisplatin | NKX2-8 deletion up-regulates FAO via the Sin3A/HDAC1/SAP18 transcriptional inhibition complex | PR | [72] |
OC | Carboplatin | – | PR | [75] |
GC | 5-FU | – | PR | [80] |
GC/CRC | 5-FU | HIF1α signaling drives transcription of HMGB1, producing high levels of GDF15 to enhance FAO | PR | |
CRC | 5-FU | CD147 inhibits PPARα-mediated FAO by activating the MAPK pathway | PR | [86] |
CML | AraC/Doxorubicin | – | PR | [90] |
AML | AraC | – | PR | [91] |
AML | AraC | SIRT3 SUMOylation can be achieved by up-regulating HES1 dependent FAO | PR | [94] |
BC | Docetaxel | CD96 and CD155 interact to activate the Src/Stat3/Opa1 pathway and enhance FAO in cancer cells | PR | [100] |
BC | Paclitaxel | Activation of the JAK/STAT3 pathway promotes up-regulation of FAO | PR | [101] |
BC | Paclitaxel | Increased FAO results in acetylation of STAT3, up-regulation of ACSL4 and further increase of mitochondrial phospholipid synthesis, leading to drug resistance of cancer cells | PR | [52] |
NSCLC | Paclitaxel | HIF-1α pathway activation down-regulates CPT1, thereby inhibiting FAO | PR | [102] |
LC | Paclitaxel | – | PR | [103] |
HCC | Doxorubicin | m6A modification promoted FAO expression by up-regulating ERRγ | PR | [107] |
TNBC | Doxorubicin | – | PR | [108] |
ALL | Daunorubicin | – | PR | [109] |
Melanoma | Etoposide | Overexpressed HIF-1α down-regulates FAO by inhibiting PPARα | PR | [25] |
MM | Bortezomib/Melphalan | IL-10 up-regulation of PPARγ/FABP5/CPT1A pathway promotes FAO up-regulation | PR | [110] |
GBM | Temozolomide | Sp1 enhanced FAO by up-regulating PGE2 | PR | [112] |
AML | Mitoxantrone | – | PR | [113] |
ALL | Dexamethasone | – | PR | [116] |
CLL | Dexamethasone | Up-regulation of PPARα led to increased FAO | PR | [117] |
